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Wide variation in susceptibility of 
transmitted/founder HIV-1 subtype 
C Isolates to protease inhibitors and 
association with in vitro replication 
efficiency
Katherine A. Sutherland1, Dami A. Collier2, Daniel T. Claiborne2, Jessica L. Prince2, 
Martin J. Deymier2, Richard A. Goldstein2, Eric Hunter2 & Ravindra K. Gupta2
The gag gene is highly polymorphic across HIV-1 subtypes and contributes to susceptibility to protease 
inhibitors (PI), a critical class of antiretrovirals that will be used in up to 2 million individuals as second-
line therapy in sub Saharan Africa by 2020. Given subtype C represents around half of all HIV-1 infections 
globally, we examined PI susceptibility in subtype C viruses from treatment-naïve individuals. PI 
susceptibility was measured in a single round infection assay of full-length, replication competent 
MJ4/gag chimeric viruses, encoding the gag gene and 142 nucleotides of pro derived from viruses in 
20 patients in the Zambia-Emory HIV Research Project acute infection cohort. Ten-fold variation in 
susceptibility to PIs atazanavir and lopinavir was observed across 20 viruses, with EC50s ranging 0.71–
6.95 nM for atazanvir and 0.64–8.54 nM for lopinavir. Ten amino acid residues in Gag correlated with 
lopinavir EC50 (p < 0.01), of which 380 K and 389I showed modest impacts on in vitro drug susceptibility. 
Finally a significant relationship between drug susceptibility and replication capacity was observed for 
atazanavir and lopinavir but not darunavir. Our findings demonstrate large variation in susceptibility of 
PI-naïve subtype C viruses that appears to correlate with replication efficiency and could impact clinical 
outcomes.
The successful global roll-out of antiretroviral therapy has resulted in approximately 15.8 million HIV positive 
individuals receiving antiretroviral therapy to date1. In resource-limited settings, 15–35% of patients experience 
therapy failure on their first-line treatment regimen (usually comprising 2 nucleoside reverse transcriptase inhib-
itors, NRTIs, and 1 non-nucleoside reverse transcriptase inhibitor, NNRTI) in the first two years2, frequently 
with high-level drug resistance to all components of the regimen3–5. WHO recommended second-line regimens 
include ritonavir boosted protease inhibitors (bPIs), particularly the PI lopinavir (LPV), and scale up of second 
line is underway6. Boosted PIs have also been used extensively in resource-rich settings as part of first-line regi-
mens and have similar efficacy to NNRTI based regimens7,8.
Despite their widespread use, the viral genetic correlates of PI resistance are not fully understood. Treatment 
failure on PI-containing regimens frequently occurs in the absence of major resistance mutations, with less than 
20% of patients developing major mutations in Protease7,9. Gag, a substrate of Protease, also affects PI susceptibil-
ity and contributes to PI resistance10. However, most previous mutations linked with PI resistance were observed 
in subtype B viruses and, in non-B subtypes, these mutations can be present as consensus or polymorphisms11–14. 
Additionally, our previous data using patient derived Gag-Protease sequences demonstrated that West African 
HIV-1 subtype CRF02_AG viruses displayed intrinsic reduced susceptibility to PIs and that their susceptibility to 
PIs pre-treatment was associated with treatment outcome15.
Subtype C HIV-1 is responsible for approximately 50% of infections globally and is most prevalent in 
Sub-Saharan Africa. PIs may target subtype C protease less efficiently and patients infected with subtype C viruses 
have poorer treatment outcomes on PI-based therapy16,17. Inclusion of co-evolved Gag affected LPV susceptibility 
1Division of Infection and Immunity, UCL, London, UK. 2Emory Vaccine Centre, Atlanta GA, USA. Correspondence 
and requests for materials should be addressed to R.K.G. (email: rebmrag@ucl.ac.uk)
Received: 31 August 2016
Accepted: 04 November 2016
Published: 30 November 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:38153 | DOI: 10.1038/srep38153
of subtype C molecular clones18 and susceptibility of resistant protease from paediatric patients failing PI-therapy 
in in vitro phenotypic assays13. However, to date there are no data on the in vitro PI susceptibility of newly trans-
mitted subtype C clinical isolates from untreated adults as measured using full-length replication competent 
chimeric viruses differing only in their patient-derived gag-protease genes19. We sought to study PI susceptibility 
and in vitro replication efficiency in a unique panel of subtype C chimeric viruses generated from acutely infected 
individuals enrolled in the Zambia-Emory HIV Research Project (ZEHRP) transmission cohort.
Materials and Methods
Study details. All participants were part of the ZEHRP discordant couples cohort, with subsequent HIV-1 
transmission20,21. Subjects for this study were acutely infected recipients who seroconverted during the obser-
vation period21. Informed consent was obtained from all subjects and ethical approval for experimental proto-
cols was obtained from both the University of Zambia Research Ethics Committee and the Emory University 
Institutional Review Board. All methods were carried out in accordance with guidelines and regulations of both 
the University of Zambia and Emory University.
Patient and clinical characteristics are shown for the twenty patients in Table 1. A positive correlation between 
patient RC and plasma viral load was previously reported in this patient cohort21. In addition an inverse correla-
tion with CD4 was noted in that study, consistent with the notion of fitter viruses leading to more rapid disease 
progression.
Plasmid construction. Patient gag and partial protease from the earliest seroconversion plasma sample was 
amplified and cloned into a subtype C infectious molecular clone MJ4, as previously described21. The resulting 
MJ4/gag chimeric vectors encoded full-length patient Gag, extending 142 nucleotides into Protease, correspond-
ing to amino acid 40. For measurement of the contribution of particular mutations, Gag-Protease was cloned into 
Gag-Pol expression vector p8.9NSX+ as previously described22. Site directed mutagenesis was performed using 
QuikChange Lightening Site-Directed Mutagenesis Kit (Agilent) as per manufacturer’s instructions.
PI susceptibility and replication capacity measurement. The replication capacity (RC) of 149 
MJ4/gag chimeric viruses had been measured in a multi-round T cell replication assay, scored and categorised 
as previously described, as listed in Table 121. Briefly, viruses were generated by transfection of 293 T cells and 
GXR25 cells were infected at a constant multiplicity. Viral production was measured in the supernatant and RC 
scores calculated, then viruses were categorised as ‘high’, ‘middle’ or ‘low’, based on the division of the distribu-
tion of viral RC scores into terciles21,23. For this study, ten viruses from each of the high and low RC categories 
were randomly selected. PI susceptibility of these twenty MJ4/Gag chimeric full-length, replication competent 
molecular clones was measured in a single round of infection as described previously24, in an assay adapted for 
replication competent virus, without a spinoculation step25. Susceptibility to the PIs lopinavir (LPV), darunavir 
(DRV) and atazanavir (ATV) was measured (NIH AIDS Reagent Program) and EC50 and EC90 were calculated for 
each PI. The PI susceptibility of the mutant viruses, generated in order to examine the effect of specific mutations 
in gag and protease, was measured in a single cycle phenotypic assay with VSV-g pseudotyped viruses produced 
using a triple-vector system, as previously described24.
Patient ID CD4 Count
Viral Load 
(copies/mL)
Replicative 
Capacity Score
Replicative 
Capacity Category
219 447 1742240 2.554 High
170 489 470712 2.836 High
259 377 654980 2.138 High
173 465 452000 2.507 High
186 533 128040 0.392 Low
255 919 732560 1.151 Low
84 399 43200 2.507 High
30 NA 200745 2.931 High
40 NA 141897 1.307 Low
159 746 2449372 2.758 High
195 878 206000 0.768 Low
167 774 16500 3.091 High
154 471 316 0.449 Low
174 612 15328 2.756 High
105 NA 17000 1.198 Low
82 682 782 1.002 Low
51 715 28396 1.104 Low
55 500 91720 0.353 Low
270 573 273000 0.355 Low
177 421 949132 2.634 High
Table 1.  Participant information; NA – not available.
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Analysis of genetic correlates. Patient gag and partial pro sequences were aligned at codon level using 
the ClustalW algorithm in MEGA 6.026. Gag sequences were examined for the presence of mutations previously 
reported to contribute to PI resistance13. Protease sequences were analysed using the Stanford Drug Resistance 
Algorithm for the presence of known resistance mutations and polymorphisms27. Additionally, a mutual infor-
mation statistical approach (with correction for multiple comparisons) was used to identify novel mutations in 
Gag associated with LPV EC5028.
Results
Large variation in PI susceptibility of viruses derived from PI-naïve patients. Up to 14-fold varia-
tion in susceptibility to the PIs ATV and LPV was observed across the 20 MJ4/Gag chimeric clinical virus isolates, 
with EC50 ranging 0.71–6.95 nM for ATV and 0.64–8.54 nM for LPV (Fig. 1a). Less variation in susceptibility to 
DRV was observed (0.96–2.55 nM). In addition, a similar distribution of PI susceptibility was observed when 
EC90 was measured (Fig. 1b).
Identification of genetic correlates of PI susceptibility. Gag cleavage sites were examined for the 
presence of amino acid residues that might correlate with PI susceptibility based on previous literature10,13 
(Supplementary Table S1). The MA/CA, CA/p2 and NC/p1 cleavage sites were largely conserved between the 
patient viruses and in comparison with consensus M sequence (Supplementary Table S1). Mutations previously 
implicated in PI susceptibility were present: 375 S (n = 2), 375 N (n = 17), I376V (n = 3), R380K (n = 7), G381S 
(n = 16), K436R (n = 2), S451N (n = 10) and P453L (n = 4) and P453T (n = 1). Of these, mutation R380K in the 
p2/NC site was more frequent in viruses with higher LPV EC50s and mutations P453L/T and I376V were enriched 
in the more susceptible viruses.
Additionally, the following known Gag non-cleavage site mutations previously associated with PI suscepti-
bility13 were present in this cohort: K30R (n = 3), G62R (n = 2), R76K (n = 6), Y79F (9), T81A (n = 1), M200I 
(n = 1), H219Q (n = 5), I389T (n = 1) and T456S (n = 2) (Supplementary Table S2). Of these, only Y79F associ-
ated with more susceptible viruses and none appeared to correlate with reduced PI susceptibility.
As MJ4/Gag chimeric vectors encoded patient Protease up to residue 40, partial Protease was examined for 
resistance mutations, as defined by the Stanford Resistance Algorithm (http://hivdb.stanford.edu). Neither major 
nor minor resistance mutations in protease were identified, but polymorphisms were present at 9 Protease posi-
tions including I15V (n = 17), K20R (n = 2), E35D (n = 5) and M36I (n = 17) (Supplementary Table S3). Only 
E35D was enriched in viruses with reduced LPV susceptibility (median EC50 = 7.88 nM).
To enable the identification of novel mutations associated with PI susceptibility we employed a mutual infor-
mation statistical approach. This approach yielded 10 amino acid positions statistically associated with LPV EC50: 
Gag 11, 18, 109, 119, 138, 182, 376, 380, 389 and 478 (Table 2). Three mutations clearly correlated with resistance 
to LPV: R18K, R380K and 478 L, and three with sensitivity: I376V, I389S/T/V and 478Q.
Modest impact of mutations at Gag positions 390 and 389 on PI susceptibility. Having identified 
mutations correlated with PI susceptibility using an in silico approach, we aimed to quantify the relative contribu-
tions of key mutations in the variation in PI susceptibility observed by means of in vitro drug susceptibility test-
ing. Two representative patient viruses were selected for further study – 170 ( termed ‘resistant’ for this analysis) 
and 177 (termed ‘sensitive’). Site directed mutagenesis was used to revert the mutations correlating with reduced 
susceptibility in patient 170 Gag-Protease, and to introduce the corresponding ‘resistance’ mutations into patient 
177 Gag-Protease. Mutants were assayed for PI susceptibility in a single cycle assay system. The effect of four 
amino acid residues significantly associated with susceptibility was studied: Gag 119, 380, 389 and protease 35, 
with mutants being assayed for PI susceptibility in a single cycle assay system.
Phenotypic PI susceptibility measurements did not demonstrate a direct effect of the reversion of resistance 
associated mutations to Gag 119Q, 380 R, 389 V and Protease 35E in Gag-Protease of patient 170, the ‘resistant’ 
virus. The reciprocal experiment introducing mutations Gag 119E, 380 K, 389I and protease 35D into patient 177 
Figure 1. Variation in PI susceptibility of patient-derived viruses to PIs LPV and ATV. The EC50 (a) and 
EC90 (b) of twenty MJ4/gag chimeric full-length molecular clones derived from acutely infected patients 
infected with subtype C virus was determined using a single replication cycle assay to the PIs atazanavir (ATV), 
lopinavir (LPV) and darunavir (DRV). Data are representative of at least 2 independent experiments.
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Gag-Protease demonstrated a small increase in EC50 (2.5 fold) for the mutations 380 K and 389I in combination, 
but other mutations showed no direct phenotypic effect when introduced singly or in combination (Fig. 2).
Finally, we hypothesised that there may be a correlation between PI susceptibility and HLA type in these 
patients, given that selective pressure on Gag can lead to CTL escape mutations in regions known to contribute to 
PI susceptibility29. We therefore examined HLA Class I haplotypes for participants and partners (Supplementary 
Tables S4 and S5) and determined associations with drug susceptibility. Due to the diversity in HLA types present 
and the relatively small number of patients, this analysis was inconclusive.
Replicative capacity is associated with PI susceptibility. High RC viruses displayed significantly 
lower PI susceptibilities than low RC viruses to LPV (LPV mean EC50 4.73 vs 2.66 nM, p = 0.0497) and ATV 
(mean 4.80 vs 2.57 nM, p = 0.0081), Fig. 3a and b. This numerical difference in susceptibility of high and low RC 
viruses to LPV and ATV was also observed when EC90 was measured with a trend towards statistical significance 
(Supplementary Figure S1). Significant variation in DRV susceptibility by RC was not observed at either the EC50 
or EC90 (Fig. 3c and Supplementary Figure S1).
Given our observation that high RC viruses had significantly higher EC50 to the PIs LPV and ATV than low 
RC viruses, we compared mutations identified as associating with susceptibility with those previously reported 
to affect RC in the ZEHRP patient cohort21. A single residue identified in our mutual information analysis was 
also identified in the previous study: 119 A was associated with increased RC but alanine was not present at this 
Patient 
Number RC
LPV EC50 
(nM) 11
Gag Amino Acid (numbered according to HXB2)
18 109 119 138 182 376 380 389 478
219 High 8.54 E R N E L Q I R I P
170 High 8.08 E K N E L Q I K I P
259 High 7.88 G R N E L T I R I L
173 High 5.71 G K N E L Q I K I M
186 Low 5.08 G R N E L Q I K DEL L
255 Low 4.77 E R N G L Q I R I L
84 High 4.22 G K N E F Q I K I V
30 High 4.00 E R N E L Q I K I S
40 Low 3.81 G K N E L Q I R I L
159 High 3.11 E K N K L Q I K I P
195 Low 3.02 E K N E L Q I K I L
167 High 2.97 G K S Q H S V R S P
154 Low 2.73 G K K E I Q I R I P
174 High 2.13 G K K K L Q V R I Q
105 Low 2.10 G K N K L Q I R I Q
82 Low 1.56 D A N E L Q V R I P
51 Low 1.45 G K N K L S I R T DEL
55 Low 1.39 G K N Q H S I R I Q
270 Low 0.70 E K K K L Q I R V P
177 High 0.64 G K N Q I Q I R V S
P value 0.00968 0.00389 0.00268 0.00145 0.00237 0.00691 0.00741 0.00039 0.00257 0.00301
Table 2.  Amino acid changes in Gag associated with LPV EC50 by mutual information analysis.
Figure 2. Direct contribution of identified mutations in Gag and Protease on PI susceptibility. PI 
susceptibility of (a) 170 (‘resistant’) and (b) 177 (‘sensitive’) and mutant viral vectors, in a PI susceptibility assay 
using VSV-g pseudotyped virus. PI susceptibility is expressed as a fold change in EC50 in comparison with the 
reference virus (black bars) which in panel (a) is 170 and in panel (b) is 177. Data are representative of at least 2 
independent experiments.
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position in our subset of patients (Table 2). Positions 373, 374 and 451 located within the Gag cleavage sites were 
also identified in the previous analysis as being associated with RC21. Alanine (A) at position 373 was associated 
with reduced RC and glutamine (Q) with higher RC, but neither of these residues were present in our patient 
subset. Mutations 374 V and 451 N were present in our patient cohort, but neither correlated significantly with 
LPV EC50 (Supplementary Table S1).
Five positions located outside of the Gag cleavage sites previously linked to PI resistance were identified in the 
previously published analysis as correlating with viral RC: 12, 30, 62, 76 and 37021. Of these mutations E12K, 62 K, 
R76K and 370 A were not statistically significant after correction for multiple comparisons and did not correlate 
with LPV EC50 in our patient subset (Supplementary Table S2). Mutation M30R was associated with higher RC 
and appeared to be enriched in patients with reduced PI susceptibility, but 30 R was only present in three high RC 
patients in this cohort.
Discussion
This is the first study to describe the variation in PI susceptibility of HIV-1 subtype C using patient specific 
Gag-Protease sequences from PI-naïve adults. Previous data has indicated that pre-treatment PI susceptibility 
correlates with treatment outcome in non-B subtypes and being infected with subtype C virus was recently asso-
ciated with poorer PI treatment outcomes in Sweden15,17.
We found that PI susceptibility to LPV, the most widely used PI in second-line therapy worldwide, varied 
by 14-fold in these MJ4/Gag chimeric patient viruses. ATV, a better tolerated PI that is increasingly used in 
second-line treatment, demonstrated 10-fold variation. This variation in susceptibility correlated with several 
mutations in Gag, including R380K which has been previously described in PI-experienced patients infected 
with subtype B virus30. Interestingly the mutations P453L and I376V, which were previously observed following 
PI exposure in patients often alongside major resistance mutations in protease, in fact correlated with increased 
susceptibility in this cohort10. Here, we observed little variation in DRV susceptibility. These data are reassuring 
given as viruses with variable susceptibility to lopinavir or atazanavir, remain fully susceptible to darunavir, a PI 
which is currently available as salvage therapy after second line failure in some settings.
We identified mutations correlating with PI susceptibility using mutual information analysis, which has previ-
ously been applied to examine PI resistance patterns in Gag and Protease, demonstrating a network of connected 
mutations across Gag and Protease in response to PI28. We were unable to demonstrate a significant direct effect 
of up to three mutations on PI susceptibility in our assay system, which is not surprising given the extensive 
variation throughout the length of Gag between patients. It is highly likely that the variation in susceptibility 
observed here is in fact conferred by a combination of mutations spread throughout Gag and possibly Protease, 
which makes the identification of the precise combinations present in each patient virus challenging. Mechanistic 
explanations for the effect of non-cleavage site mutations on drug susceptibility are likely to be diverse, and 
could include altered intra-molecular bonding as suggested by Parry et al. for a triad of matrix mutations in helix 
431. Alternatively, interactions may occur between amino acids that are apparently not in proximity based on 
sequence, suggesting physical interaction during virion maturation28.
Although we had access to HLA Class I data for the participants and partners (Supplementary Tables S4 and S5), 
we were unable to find an association between Gag mutations affecting drug susceptibility and HLA haplotype.
Our observation of an association between decreased PI susceptibility and increased RC of treatment-naïve 
viruses was unexpected and to our knowledge has not previously been described. The observation is impor-
tant given that RC was previously shown to be associated with viral load. It appears to contradict the view that 
resistant viruses are less fit, as a direct result of the reduced RC conferred by major resistance mutations32. 
However, it is important to remember that the viruses here do not contain major resistance mutations and are 
PI-naïve. Furthermore, it is highly unlikely that their transmitted partners received PI-containing therapy. We 
recently demonstrated a correlation between RC and sensitivity to interferon alpha that might be linked to the 
Figure 3. Correlation between PI susceptibility and viral replicative capacity. The EC50 of twenty MJ4/gag 
chimeric full-length molecular clones derived from acutely infected patients infected with subtype C virus was 
determined using a single replication cycle assay to the PIs atazanavir (ATV), lopinavir (LPV) and darunavir 
(DRV). Replicative capacity was determined by viral quantification of the supernatant of infected cells over 
multiple rounds of infection and then scored by terciles. PI susceptibility as a function of viral replication 
capacity is shown for the PIs (a) LPV (two sample t-test, p = 0.0497), (b) ATV (p = 0.0081) and (c) DRV 
(p = 0.1166). Data are representative of at least 2 independent experiments.
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observations presented here33, and further mechanistic investigation is warranted. Of note, viral load did not 
always correlate with RC (Table 1), consistent with the role of host factors in control of HIV replication34.
An advantage of this study is that replication competent HIV was used with an HIV-1 envelope, as opposed to 
VSV-g pseudotyped viruses used for most previous work on PI susceptibility in clinical isolates. This is particu-
larly important given recent data demonstrating that PIs can affect viral entry through an interaction between 
Gag and Envelope, an effect that is masked when a VSV-g envelope is used35. Whilst full-length Protease from the 
patient was not included in the chimeric vectors, this actually strengthens support for the hypothesis that Gag can 
affect PI susceptibility in a mechanism that is independent of compensation for resistance mutations in Protease. 
The majority of known PI resistance mutations that occur in protease are located after amino acid 40, and hence 
were not derived from the patient in this cohort. Future work should evaluate the clinical impact of variation in 
baseline PI susceptibility on the outcome of second-line PI based ART in resource limited settings, in particular 
with a view to identification of consistent genetic signatures that could be applied in a clinical diagnostic set-
ting through cheap point-of-care genotypic resistance tests36. Given the continuing roll out of standardised ART 
regimens coupled with significant rates of virological failure after one year on LPV/r based second-line therapy 
in resource limited settings37, it is vitally important that we fully understand the determinants of PI efficacy in 
second-line regimens for non-B subtypes.
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